The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.
Expert Highlights Novel Combos, Potential of Immunotherapy in MCL
April 25th 2017Stephen M. Ansell, MD, PhD, discusses emerging combinations being investigated in patients with mantle cell lymphoma, the possible role of immunotherapy, and challenges oncologists are still struggling with in this population.
Abemaciclib Improves PFS in Phase III MONARCH 3 Breast Cancer Trial
April 24th 2017Adding abemaciclib to letrozole or anastrozole improved progression-free survival compared with either aromatase inhibitor alone in women with HR+/HER2-negative breast cancer enrolled in the phase III MONARCH 3 study, according to Eli Lilly and Company, the manufacturer of the CDK4/6 inhibitor.
Complete Response to Chemo Critical in CLL Patients Who Develop Hodgkin Lymphoma
April 24th 2017Achieving a complete response following ABVD chemotherapy offered the best chance for survival for patients with chronic lymphocytic leukemia who developed Hodgkin lymphoma following Richter transformation, according to a retrospective study published in the American Journal of Hematology.
Ibrutinib Better Than Bendamustine for OS in CLL, Indirect Comparison Suggests
April 21st 2017Results of a systematic literature search published online in Clinical Lymphoma, Myeloma & Leukemia showed that ibrutinib was associated with superior survival and fewer adverse events compared with bendamustine in patients with chronic lymphocytic leukemia.
Findings Support Early Use of CD19 CAR T-Cell Therapy in Relapsed B-cell ALL
April 21st 2017Low disease burden prior to treatment with CD19-specific chimeric antigen receptor T-cell therapy appears to be a positive prognostic factor for long-term survival outcomes of patients with relapsed B-cell acute lymphoblastic leukemia.
Guideline Emphasizes Emotional, Physical Needs of Myeloma Patients
April 18th 2017There is no comprehensive, multidisciplinary guideline document for the screening, management, and long-term care of myeloma patients. The UK Myeloma Forum and the British Society for Haematology set out to address this need and published such a guideline in a recent issue of the British Journal of Hematology.
Ibrutinib Discontinuation in CLL Examined to Help Develop Salvage Approaches
April 18th 2017Patients with chronic lymphocytic leukemia who stopped treatment with ibrutinib (Imbruvica) for toxicities had longer survival than those who discontinued for other reasons, including progression and Richter transformation.
FDA Schedules ODAC Meeting for Neratinib in HER2+ Breast Cancer
April 18th 2017The FDA has scheduled an Oncologic Drugs Advisory Committee hearing for May 24, 2017, to discuss a new drug application for neratinib as a treatment for patients with HER2-positive breast cancer following prior treatment with postoperative trastuzumab, according to a statement from the developer of the TKI, Puma Biotechnology.
Novel Radiation Therapy Techniques Should Become Standard in Esophageal Cancer Management
April 17th 2017Steven H. Lin, MD, PhD discusses the benefits of advanced radiation technologies, including intensity-modulated radiation therapy and proton therapy, specifically for patients with esophageal cancer.